INOLYSIS at the 9th Systemic Sclerosis World Congress

The 9th Systemic Sclerosis World Congress, organized by the World Scleroderma Foundation, brings together leading experts to advance research in systemic sclerosis (SSc)—a severe, multi-organ fibrotic disease driven by persistent fibroblast activation and associated with high unmet medical need.

At this year’s meeting, our Founder, George Kollias, delivered a keynote on “Fibroblasts in Inflammation and Fibrosis.” His presentation highlighted the foundational science that established fibroblasts at the center of fibrotic diseases and showcased the INOLYSIS drug discovery pipeline, leading to the identification of our MVP lead, INO313, a candidate with innovative properties designed to reprogram pathogenic fibroblasts back to their homeostatic state.

At INOLYSIS, we are committed to translating this science into transformative therapies for patients with systemic sclerosis and related diseases.